E
Edda Spiekerkoetter
Researcher at Stanford University
Publications - 91
Citations - 3918
Edda Spiekerkoetter is an academic researcher from Stanford University. The author has contributed to research in topics: Pulmonary hypertension & Medicine. The author has an hindex of 26, co-authored 69 publications receiving 3351 citations. Previous affiliations of Edda Spiekerkoetter include Hannover Medical School & Cardiovascular Institute of the South.
Papers
More filters
Journal ArticleDOI
Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue
Marius M. Hoeper,Michael Schwarze,Stefan Ehlerding,Angelika Adler-Schuermeyer,Edda Spiekerkoetter,Jost Niedermeyer,Michael Hamm,Helmut Fabel +7 more
TL;DR: Long-term treatment with aerosolized iloprost is safe and has sustained effects on exercise capacity and pulmonary hemodynamics in patients with primary pulmonary hypertension.
Journal ArticleDOI
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
TL;DR: A therapeutic approach utilising combinations of bosentan, sildenafil and inhaled iloprost in conjunction with a goal-oriented treatment strategy provides acceptable long-term results in patients with severe pulmonary arterial hypertension, and reduces the need for intravenous prostaglandin treatment and lung transplantation.
Journal ArticleDOI
FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension
Edda Spiekerkoetter,Xuefei Tian,Jie Cai,Rachel K. Hopper,Deepti Sudheendra,Caiyun G. Li,Nesrine El-Bizri,Hirofumi Sawada,Roxanna Haghighat,Roshelle Chan,Leila Haghighat,Vinicio A. de Jesus Perez,Lingli Wang,Sushma Reddy,Mingming Zhao,Daniel Bernstein,David E. Solow-Cordero,Philip A. Beachy,Thomas J. Wandless,Peter ten Dijke,Marlene Rabinovitch +20 more
TL;DR: Low-dose FK506 reversed dysfunctional BMPR2 signaling in pulmonary artery endothelial cells from patients with idiopathic PAH and prevented exaggerated chronic hypoxic PAH associated with induction of EC targets of BMP signaling, such as apelin.
Journal ArticleDOI
Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids
TL;DR: It is concluded that the addition of the endothelin-receptor antagonist bosentan to inhaled iloprost or oral beraprost therapy appears to be safe for patients with primary pulmonary hypertension, resulting in a marked increase in exercise capacity.
Journal ArticleDOI
Hedgehog Signaling Restrains Bladder Cancer Progression by Eliciting Stromal Production of Urothelial Differentiation Factors
Kunyoo Shin,Agnes Lim,Chen Zhao,Debashis Sahoo,Ying Pan,Ying Pan,Edda Spiekerkoetter,Joseph C. Liao,Joseph C. Liao,Philip A. Beachy +9 more
TL;DR: It is found that despite its initial presence in the cancer cell of origin Sonic hedgehog expression is invariably lost during progression to invasive urothelial carcinoma, and progression is dramatically reduced by pharmacological activation of BMP pathway activity with low-dose FK506, suggesting an approach to management of human bladder cancer.